The company specialises in making tablet versions of drugs that are normally taken as infusions.
The products it's seeking to have licensed are tablet versions of a drug that tackles bone-weakening in late-stage cancer sufferers, and is also used to delay the recurrence of tumours in early-stage breast-cancer patients.
The European Medicines Agency has agreed to allow Merrion carry out a study on 300 patients that, if successful, would allow the drug focusing on late-stage sufferers to be sold in Europe within three years.
Help employers find you! Check out all the jobs and post your resume.
The products it's seeking to have licensed are tablet versions of a drug that tackles bone-weakening in late-stage cancer sufferers, and is also used to delay the recurrence of tumours in early-stage breast-cancer patients.
The European Medicines Agency has agreed to allow Merrion carry out a study on 300 patients that, if successful, would allow the drug focusing on late-stage sufferers to be sold in Europe within three years.
Help employers find you! Check out all the jobs and post your resume.
